Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page
- Check5 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, signaling a small maintenance update to the page. It does not indicate changes to the study results or core information.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page's revision tag updates from v3.6.3 to v3.6.4, reflecting a newer internal version in the footer.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedThe page shows a revision tag updated from Revision: v3.6.2 to Revision: v3.6.3, indicating a platform update. This change does not modify the study details, eligibility criteria, outcomes, or other content presented on the page.SummaryDifference0.1%

- Check48 days agoChange DetectedFooter revision updated from v3.6.0 to v3.6.2, signaling a minor platform update to the Study page. This change does not modify study content or visible functionality.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded recruitment status text No longer looking for participants and new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study) with a formatting update to the Intervention/Treatment label. Removed the old Intervention / Treatment heading and updated the revision to Revision: v3.6.0 replacing v3.5.5.SummaryDifference0.4%

- Check69 days agoChange DetectedThe page's revision label was updated to v3.5.5, replacing the previous v3.5.4. This reflects a minor maintenance update rather than a content change.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.